雪榕生物(300511.SZ):定增申請收到深交所意見吿知函
格隆匯 2 月 17日丨雪榕生物(300511.SZ)公佈,公司於2021年2月10日收到深交所上市審核中心出具的《關於上海雪榕生物科技股份有限公司申請向特定對象發行股票的審核中心意見吿知函》,深交所發行上市審核機構對公司向特定對象發行股票的申請文件進行了審核,認為公司符合發行條件、上市條件和信息披露要求,後續深交所將按規定報中國證監會履行相關注冊程序。根據《吿知函》要求,公司應在收到《吿知函》後以臨時公吿方式及時做好信息披露工作,在五個工作日內報送募集説明書(註冊稿)及相關文件,同時報送誠信記錄核查表,並在十個工作日內彙總補充報送與審核問詢回覆相關的保薦工作底稿。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.